Insights Into the Role of Angiotensin-II AT1 Receptor-Dependent β-Arrestin Signaling in Cardiovascular Disease

NM Mathieu, P Nakagawa, JL Grobe, CD Sigmund - Hypertension, 2024 - Am Heart Assoc
β-arrestins are a family of intracellular signaling proteins that play a key role in regulating the
activity of G protein-coupled receptors. The angiotensin-II type 1 receptor is an important G …

[PDF][PDF] 生物靶向治疗高血压的研究进展

秦萍, 廖玉华, 邱志华 - 临床心血管病杂志, 2023 - lcxxgen.whuhzzs.com
针对高血压这一主要心血管病危险因素进行有效防治, 可以降低心血管病死亡风险. 然而,
中国高血压的知晓率, 治疗率和控制率均处于较低水平, 尤其是控制率极低 …

A novel vaccine targeting β1-adrenergic receptor

F Ke, W Kuang, X Hu, C Li, W Ma, D Shi, X Li… - Hypertension …, 2023 - nature.com
Beta-blockers are widely used in the treatment of hypertension, heart failure and ischemic
heart disease. However, unstandardized medication results in diverse clinical outcomes in …

miRNAs through β-ARR2/p-ERK1/2 pathway regulate the VSMC proliferation and migration

G Ghasempour, A Mohammadi, F Zamani-Garmsiri… - Life Sciences, 2021 - Elsevier
Background miRNAs are involved in plaque formation of atherosclerosis and vessel
restenosis. In this study, we investigated the effects of miR-599, miR-204, and miR-181b on …

[PDF][PDF] 心血管病迎来生物技术药治疗的新时代

廖玉华, 程翔, 程龙献 - 临床心血管病杂志, 2023 - lcxxgen.whuhzzs.com
近年来, 生物技术药研发涌现于心血管病治疗, 包括多肽, 单克隆抗体, 反义寡核苷酸,
小干扰核糖核酸, 基因编辑疗法和治疗性疫苗. 这些信息令人鼓舞, 部分药物已经批准临床应用 …

Cardiovascular disease is ushering in a new era of biotechnological drugs therapy

L Yuhua, C Xiang, C Longxian - J Clin Cardiol, 2023 - lcxxgen.whuhzzs.com
In recent years, biotechnology drugs are emerging in the treatment of cardiovascular
disease, include polypeptides, monoclonal antibody (mAb), antisense oligonucleotide …

Progress of bio-targeted treatment for hypertension

QIN Ping, L Yuhua, QIU Zhihua - J Clin Cardiol, 2023 - lcxxgen.whuhzzs.com
Effective prevention and treatment of hypertension reduce the risk of cardiovascular death.
However, the rate of awareness, treatment, and control for hypertension in China is still low …